Abstract
Ligands that act at γ-aminobutyric type A (GABAA) receptors, in particular the benzodiazepines and related drugs, have broad clinical use but also the liability for abuse and dependence. Recent epidemiological data suggest that abuse of benzodiazepine-type drugs may be on the upswing, with a shift from primary misuse of benzodiazepines by people in a therapeutic setting to use by younger people engaging in recreational abuse. Laboratory findings suggest that benzodiazepine-type drugs have reinforcing effects both in human and non-human subjects. However, benzodiazepine-type drugs appear to have lower reinforcing effectiveness compared to other drugs of abuse, such as psychomotor stimulants. Recent research has begun to explore the role of GABAA receptor subtypes in the reinforcing effects of benzodiazepine-type drugs, and unlike other behavioral effects (e.g., motor coordination deficits); reinforcing effects are not easily attributed to a single receptor subtype. Perhaps the most firm conclusion that can be made at this point is that stimulation of GABAA receptors containing α1 subunits (α1GABAA receptors) is not necessary for self-administration of benzodiazepine-type compounds. Benzodiazepine use also is associated with physical dependence, characterized by a withdrawal syndrome. In both human and non-human subjects, this withdrawal syndrome is considered to be intermediate in severity. Preliminary results suggest that compounds with selectivity for α2GABAA, α3GABAA, and/or α5GABAA receptors do not induce physical dependence. As with reinforcing effects, systematic studies with selective compounds having relatively high intrinsic efficacy at particular subtypes should shed light on theses important mechanistic issues.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Höld, K. M., Sirisoma, N. S., Ikeda, T., Narahashi, T., and Casida, J. E. (2000) α-Thujone (the active component of absinthe): γ-Aminobutyric acid type A receptor modulation and metabolic detoxification. Proc. Natl. Acad. Sci. USA 97, 3826–3831.
Kumar, S., Fleming, R. L., and Morrow, A. L. (2004) Ethanol regulation of γ-aminobutyric acidA receptors: genomic and nongenomic mechanisms. Pharmacol. Ther. 101, 211–226.
Ator, N. A. and Griffiths, R. R. (1987) Self-administration of barbiturates and benzodiazepines: A review. Pharmacol. Biochem. Behav. 27, 391–398.
Tone, A. (2005) Listening to the past: history, psychiatry, and anxiety. Can. J. Psychiatry 50, 373–380.
Woods, J. H. and Winger, G. (1995) Current benzodiazepine issues. Psychopharmacology 118, 107–115.
Nutt, D. J. (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49–56.
Griffiths, R. R. (1995) Commentary on review by Woods and Winger. Benzodiazepines: long-term use among patients is a concern and abuse among polydrug abusers is not trivial. Psychopharmacology 118, 116–117.
Pritchett, D. B., Lüddens, H., and Seeburg, P. H. (1989) Type I and type II GABAA benzodiazepine receptor produced in transfected cells. Science 245, 1389–1392.
Löw, K., Crestani, F., Keist, R., et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131–134.
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype. Nature Neurosci. 3, 587–592.
Rudolph, U., Crestani, F., and Möhler, H. (2000) GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22, 188–194.
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., and Dawson, G. R. (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA 102, 915–920.
McKernan, R. M. and Whiting, P. J. (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Pharmacol. Sci. 19, 139–143.
Collinson, N., Kuenzi, F. M., Jarolimek, W., et al. (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor J. Neurosci. 22, 5572–5580.
Crestani, F., Keist, R., Fritschy, J. M., et al. (2002) Trace fear conditioning involves hippocampal α5 GABAA receptors. Proc. Natl. Acad. Sci. USA 99, 8980–8985.
Speaker, S. (1997) From “happiness pills” to “national nightmare”: changing cultural assessment of minor tranquilizers in America, 1955–1980. J. Hist. Med. Allied Sci. 52, 338–376.
Gordon, B. (1979) I’m Dancing as Fast as I Can. Harper & Row, New York, NY.
US Committee on Labor and Human Resources (1979) Use and misuse of benzodiazepines. Washington DC, US. Government Printing Office.
Ator, N. A. (2005) Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 10, 31–39.
Woods, J. H., Katz, J. L., and Winger, G. (1987) Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 39, 251–419.
Woods, J. H., Katz, J. L., and Winger, G. (1992) Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 44, 151–347.
Rosenbaum, J. F. (2005) Attitudes toward benzodiazepines over the years. J. Clin. Psychiatry 66, 4–8.
Griffiths, R. R. and Weerts, E. M. (1997) Benzodiazepine self-administration in humans and laboratory animals — implications for problems of long-term use and abuse. Psychopharmacology 134, 1–37.
Griffiths, R. R. and Johnson, M. W. (2005) Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry 66, 31–41.
Crane, E. H. and Nemanski, N. (2004) Benzodiazepines in drug abuse-related emergency department visits: 1995–2002. The DAWN Report, April 2004, Office of Applied Studies, US Substance Abuse and Mental Health Services Administration (available online at http://dawninfo.samhsa.gov/). Last accessed: January 3, 2007.
Crane, E. H. and Nemanski, N. (2004) Demographic characteristics of benzodiazepine-involved ED visits. The DAWN Report, July 2004, Office of Applied Studies, US Substance Abuse and Mental Health Services Administration (available online at http://dawninfo.samhsa.gov/). Last accessed: January 3, 2007.
The DASIS Report (2005) Characteristics of primary tranquilizer admissions: 2002. Drug and Alcohol Services Information System, Office of Applied Studies, Substance Abuse and Mental Health Services Administration (available online at http://www.oas.samhsa.gov). Last accessed: January 3, 2007.
Ciraulo, D. A., Sands, B. F., and Shader, R. I. (1988) Critical review of liability for benzodiazepine abuse among alcoholics. Am. J. Psychiatry 145, 1501–1506.
de Wit, H. and Doty, P. (1993) Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. Psychopharmacology 115, 529–538.
Evans, S. M., Griffiths, R. R., and de Wit, H. (1996) Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacology 123, 154–163.
Sobel, K. G. and McCart, G. M. (1983) Drug use and accidental falls in an intermediate care facility. Drug Intell. Clin. Pharm. 17, 539–542.
Herings, R. M., Stricker, B. H., de Boer, A., Bakker, A., and Sturmans, F. (1995) Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch. Intern. Med. 155, 1801–1807.
Ator, N. A. and Griffiths, R. R. (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 70, S55–S72.
Griffiths, R. R., Bigelow, G. E., and Ator, N. A. (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70, S41–S54.
Lelas, S., Spealman, R. D., and Rowlett, J. K. (2000) Using behavior to elucidate receptor mechanisms: A review of the discriminative stimulus effects of benzodiazepines. Exp. Clin. Psychopharmacol. 8, 294–311.
Helmus, T. C., Tancer, M., and Johanson, C. E. (2005) Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp. Clin. Psychopharmacol. 13, 348–356.
Iguchi, M. Y., Handelsman, L., Bickel, W. K., and Griffiths, R. R. (1993) Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 32, 257–266.
Darke, S. G., Ross, J. E., and Hall, W. D. (1995) Benzodiazepine use among injecting heroin users. Med. J. Aust. 162, 645–647.
Perera, K. M., Tulley, M., and Jenner, F. A. (1987) The use of benzodiazepines among drug addicts. Br. J. Addict. 82, 511–515.
Gelkopf, M., Bleich, A., Hayward, R., Bodner, G., and Adelson, M. (1999) Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 55, 63–68.
Bergman, J. and Johanson, C. E. (1985) The reinforcing properties of diazepam under several conditions in the rhesus monkey. Psychopharmacology 86, 108–113.
Griffiths, R. R., Lamb, R. J., Sannerud, C. A., Ator, N. A., and Brady, J. V. (1991) Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 103, 154–161.
Broadbear, J. H., Winger, G., and Woods, J. H. (2005) Self-administration of methohexital, midazolam and ethanol: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology 178, 83–91.
Winger, G., Stitzer, M. L., and Woods, J. H. (1975) Barbiturate-reinforced responding in rhesus monkeys: comparisons of drugs with different durations of action. J. Pharmacol. Exp. Ther. 195, 505–514.
Rowlett, J. K., Rodefer, J. S., and Spealman, R. D. (2002) Self-administration of cocaine, alfentanil, and nalbuphine under progressive-ratio schedules: Consumer demand and labor supply analysis of relative reinforcing effectiveness. Exp. Clin. Psychopharmacol. 10, 367–375.
Weerts, E. M., Kaminski, B. J., and Griffiths, R. R. (1998) Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Psychopharmacology 135, 70–81.
Griffiths, R. R., Sannerud, C. A., Ator, N. A., and Brady, J. V. (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J. Pharmacol. Exp. Ther. 260, 1199–1208.
Ator, N. A. (2000) Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend. 24, 55–68.
Atack, J. R., Wafford, K. A., Tye, S. J., et al. (2006) TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-30ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine], an agonist selective for α2 and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 316, 410–422.
Dawson, G. R., Collinson, N., and Atack, J. R. (2005) Development of subtype selective GABAA modulators. CNS Spectr. 10, 21–27.
Ashton, H. (1991) Protracted withdrawal syndromes from benzodiazepines. J. Subst. Abuse Treat. 8, 19–28.
Petursson, H. (1994) The benzodiazepine withdrawal syndrome. Addiction. 89, 1455–1459.
Mintzer, M. Z. and Griffiths, R. R. (2005) Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. Psychopharmacology 178, 259–267.
O’Brien, C. P. (2005) Benzodiazepine use, abuse, and dependence. J. Clin. Psychiatry 66, 28–33.
Orsini, A., Brancato, V., and Smeraldi, E. (1990) Length of anxiolytic treatment and benzodiazepine withdrawal symptoms: a double blind study with clotiazepam. New Trends Exp. Clin. Psychiatry 6, 45–52.
Mintzer, M. Z., Stoller, K. B., and Griffiths, R. R. (1999) A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology 147, 200–209.
Roth, T., Walsh, J. K., Krystal, A., Wessel, T., and Roehrs, T. A. (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 6, 487–495.
Martin, J. R., Moreau, J. L., Jenck, F., and Pieri, L. (1998) Sarmazenil-precipitated withdrawal: A reliable method for assessing dependence liability of benzodiazepine receptor ligands. Pharmacol. Biochem. Behav. 59, 939–944.
Kaminski, B. J., Sannerud, C. A., Weerts, E. M., Lamb, R. J., and Griffiths, R. R. (2003) Physical dependence in baboons chronically treated with low and high doses of diazepam. Behav. Pharmacol. 14, 331–342.
Mirza, N. R. and Nielsen, E. Ø. (2006) Do subtype-selective GABAA receptor modulators have a reduced propensity to induce physical dependence in mice? J. Pharmacol. Exp. Ther. 316, 1378–1385.
Weerts, E. M., Ator, N. A., Grech, D. M., and Griffiths, R. R. (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J. Pharmacol. Exp. Ther. 285, 41–53.
McMahon, L. R., Gerak, L. R., and France, C. P. (2001) Potency of positive γ-aminobutyric acidA modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys. J. Pharmacol. Exp. Ther. 298, 1227–1235.
Lukas, S. E. and Griffiths R. R. (1982) Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science 217, 1161–1163.
Grant, S. J., Galloway, M. P., Mayor, R., et al. (1985) Precipitated diazepam withdrawal elevates noradrenergic metabolism in primate brain. Eur. J. Pharmacol. 107, 127–132.
Gallager, D. W., Heninger, K., and Heninger, G. (1986) Periodic benzodiazepine antagonist administration prevents benzodiazepine withdrawal symptoms in primates. Eur. J. Pharmacol. 132, 31–38.
Lukas, S. E. and Griffiths, R. R. (1984) Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure. Eur. J. Pharmacol. 100, 163–171.
Sloan, J. W., Martin, W. R., and Wala, E. (1993) Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J. Pharmacol. Exp. Ther. 265, 1152–1162.
Allison, C. and Pratt, J. A. (2003) Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol. Ther. 98, 171–195.
Perrault, G., Morel, E., Sanger, D. J., and Zivkovic, B. (1992) Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J. Pharmacol. Exp. Ther. 263, 298–303.
Elliot, E. E. and White, J. M. (2000) Precipitated and spontaneous withdrawal following administration of lorazepam but not zolpidem. Pharmacol. Biochem. Behav. 66, 361–369.
Weerts, E. M. and Griffiths, R. R. (1998) Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav. Pharmacol. 9, 285–297.
Ator, N. A., Weerts, E. M., Kaminski, B. J., Kautz, M. A., and Griffiths, R. R. (2000) Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend. 61, 69–84.
Cowley, D. S., Roy-Byrne, P. P., Radant, A., et al. (1995) Benzodiazepine sensitivity in panic disorder: Effects of chronic alprazolam treatment. Neuropsychopharmacology 12, 147–157.
Stoops, W. W. and Rush, C. R. (2003) Differential effects in humans after repeated asministratios of zolpidem and triazlolam. Am. J. Drug Alcohol Abuse. 29, 281–299.
Smith, A. J., Alder, L., Silk, J., et al. (2001) Effect of a subunit on allosteric modulation of ion channel function in stably expressed human recombinant γ-aminobutyric acidA receptors determined using 36Cl ion flux. Mol. Pharmacol. 59, 1108–1118.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Rowlett, J.K., Duke, A.N., Platt, D.M. (2007). Abuse and Dependence Liability of GABAA-Receptor Modulators. In: Enna, S.J., Möhler, H. (eds) The GABA Receptors. The Receptors. Humana Press. https://doi.org/10.1007/978-1-59745-465-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-59745-465-0_7
Publisher Name: Humana Press
Print ISBN: 978-1-58829-813-3
Online ISBN: 978-1-59745-465-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)